EGI
AUTL icon

EAM Global Investors’s Autolus Therapeutics AUTL Stock Holding History

EAM Global Investors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-118,721
Closed -$757K – 93
2024
Q1 		$757K Hold
118,721
– – 0.18% 88
2023
Q4 		$765K Buy
+118,721
New +$453K 0.18% 96

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM Global Investors's AUTL Position: Q2 2024 in Review

EAM Global Investors sold out of Autolus Therapeutics (AUTL) in Q2 2024, closing a stake of 118,721 shares — an estimated $757K sold.

EAM Global Investors first reported a position in AUTL in Q4 2023 and held it in 2 quarters. The position peaked at $765K in Q4 2023. 111 funds tracked by Wall St. Rank hold AUTL as of Q2 2024.

  • EAM Global Investors reported no remaining Autolus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EAM Global Investors sold 118,721 Autolus Therapeutics shares in Q2 2024, an estimated $757K.
  • EAM Global Investors first reported a position in Autolus Therapeutics in Q4 2023 and held it in 2 quarters.
  • EAM Global Investors's Autolus Therapeutics position peaked at $765K in Q4 2023.
  • 111 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2024.

Based on EAM Global Investors's 13F filing for Q2 2024, filed 12 Aug 2024.